Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $380.00 | Overweight | Wells Fargo |
8/1/2024 | $325.00 → $375.00 | Market Perform → Outperform | Leerink Partners |
6/3/2024 | $320.00 | Hold | Jefferies |
11/13/2023 | $270.00 → $230.00 | Equal Weight → Underweight | Barclays |
9/28/2023 | $280.00 | Mkt Perform | Bernstein |
7/31/2023 | $275.00 | Overweight → Equal Weight | Barclays |
7/31/2023 | $285.00 → $270.00 | Outperform → In-line | Evercore ISI |
12/14/2022 | $350.00 | Hold | Deutsche Bank |
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currencyGAAP EPS of $2.40; earnings exceeded guidance with non-GAAP EPS of $2.63, led by strong operational performanceBeat driven by better-than-expected performance in China, as well as higher-than-expected M&A contribution to overall sales from WyattEx-China organic constant currency sales growth as expected across Pharma, Industrial, and Academic & Government end marketsFull-year outlook reflects the potential for a more gradual market improvement in the second half of the year than previously anticipatedSecond Quarter 2024 MILFORD, Mass., July 31, 2024 /PRNewswire/
News Summary: Reduces sample volume requirements by 25x through use of advanced microfluidic technologies while increasing throughput up to 24x compared with competitor capillary DSC technologiesi.Streamlines thermal stability testing of biologics using disposable microfluidic chips (MFCs) enabling analysis under actual high-concentration drug dosing and use conditions.Delivers faster and more accurate measurements of high-concentration biological drug formulationsii with unique design that simplifies sample preparation and accelerates drug development.MILFORD, Mass., July 23, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced today the global release of the TA Instruments™ Rapid
4 - WATERS CORP /DE/ (0001000697) (Issuer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,
Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment
Wells Fargo initiated coverage of Waters with a rating of Overweight and set a new price target of $380.00
Leerink Partners upgraded Waters from Market Perform to Outperform and set a new price target of $375.00 from $325.00 previously
Jefferies resumed coverage of Waters with a rating of Hold and set a new price target of $320.00
Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:WAT) with a In-Line and lowers the price target from $320 to $300.
Across the recent three months, 6 analysts have shared their insights on Waters (NYSE:WAT), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 2 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 0 0 3 1 0 3M Ago 0 0 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $318.67, a high estimate of $358.00, and a low estimate of $275.00. Experiencing a 0.1% decline,
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Underweight and lowers the price target from $295 to $275.
4 - WATERS CORP /DE/ (0001000697) (Issuer)
3 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currencyGAAP EPS of $2.40; earnings exceeded guidance with non-GAAP EPS of $2.63, led by strong operational performanceBeat driven by better-than-expected performance in China, as well as higher-than-expected M&A contribution to overall sales from WyattEx-China organic constant currency sales growth as expected across Pharma, Industrial, and Academic & Government end marketsFull-year outlook reflects the potential for a more gradual market improvement in the second half of the year than previously anticipatedSecond Quarter 2024 MILFORD, Mass., July 31, 2024 /PRNewswire/
MILFORD, Mass., July 2, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2024 financial results conference call live on Wednesday, July 31st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least August 28th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. Wit
Highlights Sales of $637 million at the high-end of guidance, declined 7% as reported and 9% in organic constant currencyGAAP EPS of $1.72; earnings well above guidance, with non-GAAP EPS of $2.21Operational excellence drove gross margin expansion of 40 basis points and adjusted operating margin expansion of 20 basis pointsStrong operating cash flow generation at $263 million; free cash flow of $234 million was 37% of sales Full-year guidance maintained at -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05First Quarter 2024 MILFORD, Mass., May 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the first qua